metformin has been researched along with Polycystic Kidney Diseases in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Polycystic Kidney Diseases: Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin was administrated through daily intraperitoneal injection from postnatal day 35 for 4 weeks." | 7.11 | Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. ( Chang, MY; Chou, LF; Hsu, SH; Hung, CC; Ong, ACM; Tian, YC; Tsai, CY; Yang, CW; Yang, HY, 2022) |
| "Metformin (MET) has the potential to activate p-AMPK and block mTORC1-induced proliferation of tubular cells in PKD kidneys." | 5.91 | Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. ( Atwood, DJ; Chaudhary, A; Edelstein, CL; He, Z; Li, AS; Oto, OA; Wempe, MF, 2023) |
| "Metformin was administrated through daily intraperitoneal injection from postnatal day 35 for 4 weeks." | 3.11 | Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. ( Chang, MY; Chou, LF; Hsu, SH; Hung, CC; Ong, ACM; Tian, YC; Tsai, CY; Yang, CW; Yang, HY, 2022) |
| "Metformin (MET) has the potential to activate p-AMPK and block mTORC1-induced proliferation of tubular cells in PKD kidneys." | 1.91 | Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. ( Atwood, DJ; Chaudhary, A; Edelstein, CL; He, Z; Li, AS; Oto, OA; Wempe, MF, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MY | 1 |
| Tsai, CY | 1 |
| Chou, LF | 1 |
| Hsu, SH | 1 |
| Yang, HY | 1 |
| Hung, CC | 1 |
| Tian, YC | 1 |
| Ong, ACM | 1 |
| Yang, CW | 1 |
| Oto, OA | 1 |
| Atwood, DJ | 1 |
| Chaudhary, A | 1 |
| He, Z | 1 |
| Li, AS | 1 |
| Wempe, MF | 1 |
| Edelstein, CL | 1 |
| Leonhard, WN | 1 |
| Song, X | 1 |
| Kanhai, AA | 1 |
| Iliuta, IA | 1 |
| Bozovic, A | 1 |
| Steinberg, GR | 1 |
| Peters, DJM | 1 |
| Pei, Y | 1 |
| Wang, J | 1 |
| Chin, D | 1 |
| Poon, C | 1 |
| Mancino, V | 1 |
| Pham, J | 1 |
| Li, H | 1 |
| Ho, PY | 1 |
| Hallows, KR | 1 |
| Chung, EJ | 1 |
1 trial available for metformin and Polycystic Kidney Diseases
| Article | Year |
|---|---|
Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice.
Topics: Animals; Cysts; Disease Models, Animal; Female; Kidney; Lactic Acid; Male; Metformin; Mice; Mice, Tr | 2022 |
3 other studies available for metformin and Polycystic Kidney Diseases
| Article | Year |
|---|---|
Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease.
Topics: AMP-Activated Protein Kinases; Animals; Cysts; Humans; Lactates; Male; Metformin; Polycystic Kidney | 2023 |
Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cyclic AMP; | 2019 |
Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease.
Topics: Administration, Oral; Animals; Chitosan; Drug Carriers; Drug Delivery Systems; Humans; Metformin; Mi | 2021 |